138
Views
0
CrossRef citations to date
0
Altmetric
Editorials

The rise of innovative clinical trial designs: what’s in it for amyotrophic lateral sclerosis?

&
Pages 3-4 | Received 08 Oct 2019, Accepted 13 Oct 2019, Published online: 29 Oct 2019
 
This article responds to:
Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis

Declaration of interest

The authors declare that they have no conflict of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.